Yazar "Özkaya D." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Comparison of the proportion dilution method and E-test for ofloxacin and ciprofloxacin susceptibility testing of mycobacterium tuberculosis [Mycobacterium tuberculosis suşlarinda ofloksasi·n ve si·profloksasi·n duyarliliginin saptanmasinda standart oranti di·lüsyon i·le E-test yöntemleri·ni·n karşilaştirilmasi]
    (2001) Çavuşoglu C.; Çiçek Saydam C.; Burhanoglu D.; Özkalay N.; Özkaya D.; Özçam H.; Bilgiç A.
    In this study, the antibacterial activities of ofloxacin and ciprofloxacin on 100 clinical isolates of Mycobacterium tuberculosis were investigated by using standard proportion dilution method and E-test. The sensitivities of the isolates to conventional antibiotics (isoniazide, ethambutol, rifampin, streptomycin) were determined by Bactec system and 6 were found resistant to isoniazide, while 4 strains showed multi-drug resistance. All of the 10 resistant strains and 88 of 90 sensitive strains (98%) were found susceptible to ofloxacin and ciprofloxacin by both proportion dilution method and E-test. Two of the isolates (2%) which were susceptible to first choise antituberculous drugs, were found resistant to ofloxacin and ciprofloxacin by both of the methods. As a result, the accordance between E-test and standard proportion dilution method was detected as 100 percent.
  • Küçük Resim Yok
    Öğe
    Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: Posttreatment 1-year results of three Turkish centres
    (Maney Publishing, 2014) Yamazhan T.; Kurtaran B.; Pullukçu H.; Yüksel E.; Özkaya D.; Taşbakan M.I.; Sipahi O.R.; Durusoy R.; Salih Zeki Aksu H.
    In this study, we aimed to evaluate the 1-year post-treatment follow-up results of 112 patients who received pegylated interferon (PEG-IFN) for 52 weeks. HBeAg negativity/seroconversion and/or negative HBV-DNA at the end of the treatment were considered as response. Patients who had response at the end of treatment but had HBV-DNA breakthrough during 1-year follow-up were considered as relapse. The study group comprised 112 cases (34 HBeAg-positive, 78 HBeAg-negative). In HBeAg-positive and -negative cases, end-of-treatment response rates were 2.9% and 60.2%, whereas 1-year sustained virological response rates were 0 and 33.3%, respectively. When we compared relapse cases versus cases with response at the end of 1-year follow-up, being female and having low viral load were the two parameters associated with higher response rates (Chi-square, P50.028; Mann–Whitney U test, P50.023). Overall non-response rates to PEGIFN were high (57.1%). Results in HBeAg-positive cases were disappointing. © 2014 Edizioni Scientifiche per l’Informazione su Farmaci e Terapia.